{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:04:24Z","timestamp":1762643064167,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40120-024-00637-2","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T11:02:25Z","timestamp":1719486145000},"page":"1273-1285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing\u2013Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02634307","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-7374","authenticated-orcid":false,"given":"Barry A.","family":"Singer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibyl","family":"Wray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-8554","authenticated-orcid":false,"given":"Mark","family":"Gudesblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bumstead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Bonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-459X","authenticated-orcid":false,"given":"Matthew","family":"Scaramozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathura","family":"Shanmugasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-8360","authenticated-orcid":false,"given":"Sai L.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"637_CR1","unstructured":"Vumerity. Summary of product characteristics. Netherlands B.V: Biogen; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vumerity-epar-product-information_en.pdf. Accessed 04 Oct 2023."},{"key":"637_CR2","unstructured":"Vumerity. Prescribing information. Cambridge, MA: Biogen; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211855s009lbl.pdf. Accessed Jan 16, 2024."},{"key":"637_CR3","unstructured":"Tecfidera. Prescribing information. Cambridge, MA: Biogen; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204063s029lbl.pdf. Accessed May 25, 2023."},{"issue":"12","key":"637_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase\u00a03 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"12","key":"637_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase\u00a03 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"637_CR7","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, et al. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077\u201387.","journal-title":"Clin Ther"},{"issue":"5","key":"637_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13\u00a0years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022;28(5):801\u201316.","journal-title":"Mult Scler"},{"issue":"13","key":"637_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729\u201339.","journal-title":"Mult Scler"},{"key":"637_CR10","unstructured":"Biogen. Data on file. 2023."},{"issue":"4","key":"637_CR11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","volume":"39","author":"S Wray","year":"2022","unstructured":"Wray S, Then Bergh F, Wundes A, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase\u00a03 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810\u201331.","journal-title":"Adv Ther"},{"issue":"14","key":"637_CR12","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/13524585231205708","volume":"29","author":"BA Singer","year":"2023","unstructured":"Singer BA, Arnold DL, Drulovic J, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler. 2023;29(14):1795\u2013807.","journal-title":"Mult Scler"},{"issue":"2","key":"637_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396.","journal-title":"CNS Drugs"},{"issue":"6","key":"637_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1352458520937282","volume":"27","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2021;27(6):883\u201394.","journal-title":"Mult Scler"},{"issue":"3","key":"637_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139.","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"637_CR16","doi-asserted-by":"publisher","DOI":"10.4110\/in.2019.19.e37","volume":"19","author":"SJ Oh","year":"2019","unstructured":"Oh SJ, Lee JK, Shin OS. Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity. Immune Netw. 2019;19(6):e37.","journal-title":"Immune Netw"},{"key":"637_CR17","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the \u201creal MS.\u201d Ther Adv Neurol Disord. 2022;15:17562864211066752.","journal-title":"Ther Adv Neurol Disord"},{"key":"637_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.","journal-title":"Front Neurol"},{"key":"637_CR19","unstructured":"Mao-Draayer Y, Giles K, Balashov K, et al. Safety and effectiveness of delayed-release dimethyl fumarate in patients \u2265 55\u00a0years enrolled in the phase\u00a0IV ESTEEM study. CMSC. Seattle, WA; 2019."},{"issue":"4","key":"637_CR20","first-page":"205521732211324","volume":"8","author":"J Lyons","year":"2022","unstructured":"Lyons J, Hughes R, McCarthy K, et al. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. Mult Scler J Exp Transl Clin. 2022;8(4):20552173221132468.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"637_CR21","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/cells10113177","volume":"10","author":"S Fischer","year":"2021","unstructured":"Fischer S, Proschmann U, Akgun K, Ziemssen T. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells. 2021;10(11):3177.","journal-title":"Cells"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00637-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:32:52Z","timestamp":1721629972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00637-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00637-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Barry A Singer: research grant support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis, and Sanofi; and consulting and\/or speaking fees from AbbVie, Alexion, Biogen, Bristol Myers Squibb, Cigna, Cionic, EMD Serono, Genentech, Greenwich Biosciences, Horizon, Janssen, Novartis, Octave Bioscience, Roche, Sanofi, and TG Therapeutics. Sibyl Wray: consulting fees from and advisory boards for Biogen, Celgene, and EMD Serono; speaker bureaus for Biogen, Celgene, EMD Serono, Roche-Genentech, and Sanofi-Genzyme; research support from Biogen, Celgene, EMD Serono, Novartis, Receptos, Roche-Genentech, Sanofi-Genzyme, and TG Therapeutics. Mark Gudesblatt: speaker and consulting for Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi-Genzyme, Saol Therapeutics, and Teva Pharmaceuticals. Barbara Bumstead: speaker and consulting for Biogen, BMS, and Genzyme. Tjalf Ziemssen: personal compensation for consulting services and speaker honoraria from Biogen, BMS, Novartis, Roche, Sanofi, and Teva; and financial support for research activities from Biogen, Novartis, Roche, and Sanofi. Ashley Bonnell: speaker for EMD Serono; research support from Biogen, Celgene, EMD Serono, Novartis, Receptos, Roche-Genentech, Sanofi-Genzyme, and TG Therapeutics. Matthew Scaramozza, Seth Levin, Jason P Mendoza, Jim B Lewin, Sai L Shankar: employees of and hold stock\/stock options in Biogen. Mathura Shanmugasundaram:\u00a0was an employee of and may have held stock in Biogen at time of analysis. Currently an employee of Takeda. Hailu Chen: was an employee of and may have held stock in Biogen at time of analysis. Currently an employee of and holds stock\/stock options in Alkermes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with protocol, the International Council for Harmonization Guideline E6, all applicable local regulatory requirements, and ethical principles based on the Declaration of Helsinki. Before enrollment of patients, the study protocol was reviewed and approved by the Copernicus Group institutional review board and the independent ethics committees for each study site. A list of these committees has been published previously []. All patients provided their written and informed consent ahead of participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}